secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001193125-25-318377
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna reports positive Phase 2 topline data for miv-cel in stiff person syndrome; BLA planned 1H 2026
--------------------------------------------------------------------------------

- Primary endpoint met: 46% median improvement in timed 25-foot walk at Week 16 (p=0.0002).
- 81% of patients exceeded 20% improvement in T25FW; 67% no longer needed walking aid (12 patients).
- All secondary endpoints statistically significant (p<0.0001); 100% free of immunotherapies post-dose.
- No high-grade CRS or ICANS; manageable Grade 3/4 neutropenia observed in some patients.
- Company plans to submit BLA to FDA for SPS in first half of 2026; RMAT and Orphan Drug designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525318377/0001193125-25-318377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525318377/d285116d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-318377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer